Cargando…
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials
BACKGROUND: Clopidogrel low response (CLR) is an independent risk factor of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), and intensified antiplatelet treatments (IAT) guided by platelet function assays might overcome laboratory CLR. However, whether IAT improves...
Autores principales: | Xu, Lei, Hu, Xiao-Wei, Zhang, Shu-Hua, Li, Ji-Min, Zhu, Hui, Xu, Ke, Chen, Jun, Li, Chun-Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831535/ https://www.ncbi.nlm.nih.gov/pubmed/27064045 http://dx.doi.org/10.4103/0366-6999.179786 |
Ejemplares similares
-
Efficacy and safety of short-term (≤6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials
por: Xiang, Chun-Lin, et al.
Publicado: (2017) -
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma
por: Lai, Quirino, et al.
Publicado: (2022) -
Effects of Prior Antiplatelet Therapy on the Prognosis of Primary Intracerebral Hemorrhage: A Meta-analysis
por: Yu, Hai-Han, et al.
Publicado: (2017) -
Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies
por: Jia, Min, et al.
Publicado: (2015) -
Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)